Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVela Technologies Regulatory News (VELA)

Share Price Information for Vela Technologies (VELA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.0125
Bid: 0.012
Ask: 0.013
Change: 0.00 (0.00%)
Spread: 0.001 (8.333%)
Open: 0.0125
High: 0.0125
Low: 0.0125
Prev. Close: 0.0125
VELA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update re. Economic Interest in AZD1656

21 Sep 2023 09:01

RNS Number : 2155N
Vela Technologies PLC
21 September 2023
 

21 September 2023

Vela Technologies plc

("Vela" or "the Company")

 

Update on Put Option for potential sale of Economic Interest in AZD1656

Further to the Company's announcements on 15 August 2023, 7 September 2023 and 8 September 2023, the Board of Vela (AIM: VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, notes the announcement made by Murphy Canyon Acquisition Corp. (NASDAQ: MURF) ("Murphy") that at the special meeting of stockholders held yesterday, its initial business combination with Conduit Pharmaceuticals Limited ("Conduit") has been approved.

 

An extract of the Murphy announcement is set out below and a link to the announcement can be found here:

 

https://www.accesswire.com/786091/murphy-canyon-acquisition-corp-announces-stockholder-approval-of-the-proposed-combination-with-conduit-pharmaceuticals-limited

 

On 20 April 2023, Vela announced that the Company entered into a put option agreement to give the Company the right, but not the obligation ("the Option"), to sell its economic interest in the commercialisation of the Covid-19 application of AZD1656 for a total consideration of £4.0 million. The Option was granted by Conduit and its prospective parent company, Murphy, a Company listed on NASDAQ.

 

On 15 May 2023, Vela announced that Murphy had filed the Form S-4 Registration Statement and preliminary proxy statement with the SEC.

 

Following the approval of the business combination of Conduit and Murphy by Murphy shareholders, the Board of Vela intends to exercise the Option following the satisfaction or waiver of the remaining closing conditions as stated in the Murphy announcement.

 

The Company will release further announcements as and when appropriate.

 

Extract from Murphy announcement

 

SAN DIEGO, CA / ACCESSWIRE / September 20, 2023 / Murphy Canyon Acquisition Corp. (Nasdaq:MURF) ("MURF" or "Murphy Canyon"), a special purpose acquisition company, announced today that at a special meeting of the MURF stockholders (the "Special Meeting") held today, MURF's stockholders voted in favor of the proposed business combination (the "Business Combination") with Conduit Pharmaceuticals Limited ("Conduit") and the related proposals. As a result, the completion of the Business Combination is expected to occur as soon as practicable, subject to the satisfaction or waiver of remaining closing conditions. Following the completion of the Business Combination, the newly combined company will operate as Conduit Pharmaceuticals Inc. and its common stock and public warrants will trade on The Nasdaq Global Market under the symbols "CDT" and "CDTTW". Assuming that closing is completed on September 21, 2023, trading in the common stock and public warrants is expected to continue on Nasdaq, switching from the symbols "MURF" and "MURFW" to the new symbols "CDT" and "CDTTW", respectively, at the open of trading on September 22, 2023.

 

About Conduit

 

Conduit is a disease agnostic life science company providing an efficient model for compound development. Formed in 2019, Conduit is a departure from the traditional big pharma/biotech business model whereby, typically companies shepherd their assets through regulatory approval, Conduit acquires assets that are Phase II-ready and then seeks an exit through third-party license deals following successful clinical trials. Conduit is led by a highly experienced team of pharmaceutical executives, including Dr. David Tapolczay and Dr. Freda Lewis-Hall, and was established to fund the development of clinical molecules licensed from major pharmaceutical companies.

 

About Murphy Canyon Acquisition Corp.

 

Murphy Canyon is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Management is led by Jack Heilbron, Chief Executive Officer and Chairman of the Board of Directors. Murphy Canyon is sponsored by Murphy Canyon Acquisition Sponsor, LLC, a wholly owned subsidiary of Presidio Property Trust, Inc. (Nasdaq: SQFT), which is expected to own 4,015,250 shares of Conduit after the successful completion of the Business Combination.

 

Important Information and Where to Find It

 

This press release relates to a proposed transaction between Conduit and MURF. In connection with the proposed Business Combination, Murphy Canyon filed its registration statement on Form S-4 that includes a proxy statement with respect to the stockholder meeting of Murphy Canyon and a prospectus with respect to securities of the combined company (the "Registration Statement"). The proxy statement/prospectus was sent to all Murphy Canyon stockholders. Murphy Canyon has also filed prospectus supplements amending the proxy statement/prospectus that was sent to all Murphy Canyon stockholders. Murphy Canyon has filed and will file other documents regarding the proposed Business Combination with the U.S. Securities and Exchange Commission (the "SEC"). INVESTORS AND SECURITIES HOLDERS OF MURPHY CANYON ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS, PROSPECTUS SUPPLEMENT AND ALL OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED BUSINESS COMBINATION AS THEY BECOME AVAILABLE SINCE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED BUSINESS COMBINATION AND THE PARTIES TO THE PROPOSED BUSINESS COMBINATION.

 

Investors and securities holders are able to obtain free copies of the Registration Statement, proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by Murphy Canyon through the website maintained by the SEC at https://sec.gov/. In addition, the documents filed by Murphy Canyon may be obtained free of charge from Murphy Canyon's website at https://murphycanyonac.com or by written request to info@murphycanyonac.com. Additional information about the business combination agreement dated November 8, 2022, as amended (the "Business Combination Agreement"), and the transactions contemplated thereby (the "Transaction") and investor presentations, were provided in Current Reports on Form 8-K filed by Murphy Canyon with the SEC which can be accessed at www.sec.gov as well as online at https://murphycanyonac.com.

 

 

 

For further information, please contact:

Vela Technologies plc

Brent Fitzpatrick, Non-Executive Chairman

James Normand, Executive Director

Tel: +44 (0) 7410 886830

 

Allenby Capital Limited (Nominated Adviser)

Tel: +44 (0) 20 3328 5656

Nick Athanas / Piers Shimwell

Peterhouse Capital Limited (Broker)

Tel: +44 (0) 20 7469 0930

Lucy Williams / Duncan Vasey

Novus Communications (PR and IR Adviser)

Tel: +44 (0) 20 7448 9839

Alan Green / Jacqueline Briscoe

 

About Vela Technologies

Vela Technologies plc (AIM: VELA) is an investing company focused on early stage and pre-IPO long term disruptive technology investments. Vela's investee companies have either developed ways of utilising technology or are developing technology with a view to disrupting the businesses or sector in which they operate. Vela Technologies will also invest in already-listed companies where valuations offer additional opportunities.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDGRGDCRUDDGXB
Date   Source Headline
8th Feb 20221:30 pmRNSTR-1:Notification of major holdings
7th Feb 20227:00 amRNSQuarterly Investment Update
28th Jan 202212:00 pmRNSUpdate re. investment in Cornerstone FS plc
24th Jan 202212:33 pmRNSResult of AGM
17th Jan 20227:00 amRNS£750,000 investment in EnSilica
7th Jan 20222:15 pmRNSHolding(s) in Company
7th Jan 20222:15 pmRNSPart disposal of holding in Northcoders Group plc
31st Dec 20217:00 amRNSHalf-year Report
30th Dec 20211:10 pmRNSAGM Notice, Share Consolidation, Investing Policy
22nd Dec 20219:06 amRNSSecond Price Monitoring Extn
22nd Dec 20219:01 amRNSPrice Monitoring Extension
14th Dec 20214:41 pmRNSSecond Price Monitoring Extn
14th Dec 20214:36 pmRNSPrice Monitoring Extension
14th Dec 20217:00 amRNSUpdate re. St George Street Capital COVID-19 trial
1st Dec 20218:05 amRNS£250,000 investment in Skillcast Group plc
17th Nov 20213:10 pmRNSUpdate re. investment in WeShop Limited
21st Oct 20212:08 pmRNSUpdate re. WeShop Limited
30th Sep 20215:00 pmRNSTotal Voting Rights
30th Sep 20218:20 amRNSFinal Results
17th Sep 20217:00 amRNSUpdate re. Aeristech
16th Sep 20213:16 pmRNSUpdate re. St George Street Capital Holding
10th Sep 20214:40 pmRNSSecond Price Monitoring Extn
10th Sep 20214:35 pmRNSPrice Monitoring Extension
9th Sep 20212:05 pmRNSSecond Price Monitoring Extn
9th Sep 20212:00 pmRNSPrice Monitoring Extension
9th Sep 20217:33 amRNSUpdate re. St George Street Capital COVID-19 trial
8th Sep 20214:41 pmRNSSecond Price Monitoring Extn
8th Sep 20214:36 pmRNSPrice Monitoring Extension
7th Sep 20217:00 amRNSExercise of warrants and issue of equity
1st Sep 20217:00 amRNSAppointment of director
27th Aug 20214:41 pmRNSExercise of warrants and issue of equity
18th Aug 20217:00 amRNSUpdate re. St George Street Capital COVID-19 Trial
30th Jul 20215:00 pmRNSTotal Voting Rights
27th Jul 20218:32 amRNSCompletion of investment in Northcoders Group plc
23rd Jul 20217:00 amRNSUpdate re proposed board appointment
22nd Jul 20218:35 amRNS£750,000 investment in Northcoders Group plc
19th Jul 20219:12 amRNSExercise of warrants and issue of equity
9th Jul 202110:53 amRNSUpdate re. St George Street Capital COVID-19 Trial
7th Jul 20213:09 pmRNSExercise of warrants and issue of equity
6th Jul 20212:34 pmRNSExercise of warrants and issue of equity
12th Apr 20217:00 amRNSReplacement: Update re. St George Street Capital
9th Apr 20212:43 pmRNSSale of North Peak & update on investment activity
8th Apr 20214:00 pmRNSUpdate re. St George Street Capital COVID-19 trial
8th Apr 20217:00 amRNSHolding(s) in Company
6th Apr 20215:55 pmRNSUpdate re. investment in Cornerstone FS plc
30th Mar 20217:00 amRNSExercise of warrants and issue of equity
25th Mar 20212:15 pmRNS£200,000 investment in MTI Wireless Edge Ltd
11th Mar 20211:11 pmRNSResult of General Meeting and Total Voting Rights
2nd Mar 20211:03 pmRNSFurther investment in Mode Global Holdings plc
25th Feb 20213:03 pmRNS£350,000 pre-IPO investment in Aeristech

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.